CF Industries Q1 EBITDA Beats as Nitrogen Market Tightens; DeepValue Maintains WAIT

What happened

CF Industries reported Q1 2026 adjusted EBITDA of $983 million, citing strong operations and a tightening global nitrogen market ahead of the North American spring season. The result underscores CF's ability to generate robust cash flows amid favorable nitrogen pricing and high asset utilization. However, the DeepValue master report assigns a WAIT rating, noting that current valuation around $77 does not adequately discount a potential normalization in nitrogen prices or compression of the North American gas advantage. The report sees a better risk-reward entry near $70, where free cash flow yield would be higher, and flags execution risks from large low-carbon projects and aggressive buybacks. While the Q1 beat supports the bull case, the WAIT rating reflects caution that earnings are highly cyclical and that the market may be pricing in a more sustained boom than fundamentals warrant.

Implication

The Q1 beat validates CF's operational strength and the near-term constructive nitrogen backdrop, but the stock already trades at ~9x EPS, which we view as fair given cycle risks. The DeepValue report's base case implies $85 fair value, offering limited upside from current levels, while the bear case of $65 suggests as much downside risk as upside. Key watchpoints include nitrogen price trends post-spring, natural gas cost advantage sustainability, and capital allocation discipline amid rising decarbonization capex. The CFO transition adds a governance overhang, though it appears orderly; however, it introduces uncertainty around future capital allocation priorities. We recommend staying patient, keeping a trim above $95 target, and looking to add nearer $70 if the cycle softens or gas spreads compress unexpectedly.

Thesis delta

The Q1 EBITDA beat is consistent with the bull case but does not shift the probability-weighted outcome meaningfully. The WAIT rating remains appropriate as valuation does not offer an adequate margin of safety for mid-cycle normalization risks. The report's conviction stays at 3.5/5, suggesting a modest positive tilt but not yet an attractive entry.